5,956 Shares in Illumina, Inc. $ILMN Bought by Wick Capital Partners LLC

Wick Capital Partners LLC bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 5,956 shares of the life sciences company’s stock, valued at approximately $781,000.

Other hedge funds have also recently bought and sold shares of the company. Empowered Funds LLC increased its holdings in shares of Illumina by 113.7% during the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC bought a new stake in shares of Illumina in the second quarter valued at about $621,000. CW Advisors LLC bought a new stake in shares of Illumina in the second quarter valued at about $275,000. Marshall Wace LLP grew its position in Illumina by 49.0% during the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after buying an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC grew its position in Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after buying an additional 1,748 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CAO Scott D. Ericksen sold 500 shares of the business’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $80,000.00. Following the sale, the chief accounting officer owned 14,446 shares of the company’s stock, valued at $2,311,360. The trade was a 3.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the sale, the senior vice president directly owned 21,259 shares in the company, valued at approximately $3,456,500.81. This represents a 3.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,003,154 shares of company stock worth $155,600,208. Insiders own 2.90% of the company’s stock.

Illumina Stock Performance

NASDAQ ILMN opened at $161.93 on Friday. The stock has a market cap of $24.50 billion, a P/E ratio of 29.44, a PEG ratio of 2.98 and a beta of 1.50. The company’s 50-day simple moving average is $144.52 and its 200 day simple moving average is $135.98. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $177.22. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, research analysts forecast that Illumina, Inc. will post 5.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the topic of several research reports. JPMorgan Chase & Co. upgraded Illumina from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $125.00 to $185.00 in a research note on Wednesday, June 10th. Wall Street Zen downgraded Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Barclays lifted their price objective on Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a report on Friday, May 1st. Evercore restated an “outperform” rating on shares of Illumina in a research report on Friday, May 1st. Finally, Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $142.12.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.